好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identification of Paramagnetic Rim Lesions Using off the Shelf Phase Maps
Multiple Sclerosis
P5 - Poster Session 5 (11:45 AM-12:45 PM)
19-008

In this cross-sectional study we assess inter-rater level of agreement (LoA) on PRL identification using a T2*-weighted (T2*-w) 3-dimensional echo-planar imaging (3D-EPI)-derived phase images at 3 Tesla (3T) and a single-echo (SE) gradient-echo (GRE)-derived phase and susceptibility-weighted imaging (SWI) at 7 Tesla (7T).

Paramagnetic rim lesions (PRLs) are an important magnetic resonance imaging (MRI) biomarker in multiple sclerosis (MS), with proposed inclusion in updated diagnostic criteria. Consequently, an accurate identification of PRLs using clinically accessible, vendor-provided MRI sequences is vital for routine practice.

Twenty-eight newly diagnosed, treatment-naïve people with MS, clinically isolated syndrome (CIS), or radiologically isolated syndrome (RIS) underwent brain MRI at both 3T and 7T. The 3T protocol included T2-weighted fluid attenuated inversion recovery (T2w-FLAIR) sequence and T2*w-3D-EPI GRE sequences. The 7T protocol included T2w-FLAIR and SE-GRE sequences. PRLs were prospectively assessed by three independent raters using the 3T T2*w-3D-EPI derived phase map, and 7T SE-GRE derived phase and SWI maps, following the North American Imaging of MS criteria. Inter-rater and rater-to-consensus LoA were evaluated using Cohen’s kappa (κ). Sensitivity and specificity of each sequence were calculated against 7T SWI.

PRLs were more frequently detected on 7T SWI (n=37, 5.2%) and 7T phase (n=35, 5.0%) than on 3T phase (n=25, 3.5%) (p<0.001 for both comparisons). Inter-rater LoA was substantial on 3T phase (κ=0.66–0.74), substantial to almost perfect on 7T phase (κ=0.76–0.82) and almost perfect on 7T SWI (κ=0.82–0.90). Compared to 7T SWI, 3T phase showed substantial LoA (κ=0.75), with 99.6% specificity and 66.7% sensitivity. The LoA between 7T phase and SWI was nearly perfect (κ=0.96).

3T phase imaging demonstrates substantial agreement and high specificity relative to 7T SWI, supporting its clinical utility as a practical alternative for PRL detection.

Authors/Disclosures
Ahmad A. Toubasi, MD (Vanderbilt University Medical Center)
PRESENTER
Dr. Toubasi has nothing to disclose.
Zachery Rohm, MD Dr. Rohm has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Rohm has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Rohm has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for City of Chicago.
Jinming Wang Mr. Wang has nothing to disclose.
Taegan V. Vinarsky Miss Vinarsky has nothing to disclose.
Caroline Gheen Ms. Gheen has nothing to disclose.
Ellie K. McCluey, Undergraduate Student Ms. McCluey has nothing to disclose.
chaoyue zhang, DO Dr. zhang has nothing to disclose.
Eric Brian, BS/BA Mr. Brian has received research support from National MS Society.
Marc Graham Mr. Graham has nothing to disclose.
Carynn E. Koch, MD (Vanderbilt University Medical Center) Dr. Koch has nothing to disclose.
Stephanie Taylor, MD (Vanderbilt University Medical Center) Dr. Taylor has nothing to disclose.
Junzhong Xu, PhD Dr. Xu has received personal compensation for serving as an employee of Vanderbilt University Medical Center.
Francesca Bagnato, MD (Vanderbilt University Medical Center) Dr. Bagnato has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Bagnato has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyne. Dr. Bagnato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Bagnato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jenseen. Dr. Bagnato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merk-Serono.